BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 15647013)

  • 1. Multiple red cell alloantibodies, including anti-Dib, after allogeneic ABO-matched peripheral blood progenitor cell transplantation.
    Zupańska B; Zaucha JM; Michalewska B; Malinowska A; Brojer E; Hellmann A
    Transfusion; 2005 Jan; 45(1):16-20. PubMed ID: 15647013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. After major ABO-mismatched allogeneic hematopoietic progenitor cell transplantation, erythroid engraftment occurs later in patients with donor blood group A than donor blood group B.
    Schetelig J; Breitschaft A; Kröger N; Zabelina T; Ebell W; Bornhäuser M; Haack A; Ehninger G; Salama A; Siegert W;
    Transfusion; 2005 May; 45(5):779-87. PubMed ID: 15847669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic peripheral blood hematopoietic stem cell transplantation: guidelines for red blood cell immuno-hematological assessment and transfusion practice.Société Française de Greffe de Moelle.
    Lapierre V; Kuentz M; Tiberghien P
    Bone Marrow Transplant; 2000 Mar; 25(5):507-12. PubMed ID: 10713627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch.
    Scholl S; Klink A; Mügge LO; Schilling K; Höffken K; Sayer HG
    Transfusion; 2005 Oct; 45(10):1676-83. PubMed ID: 16181220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Major ABO-incompatible hematopoietic stem cell transplantation: study of post-transplant pure red cell aplasia and endothelial cell chimerism.
    Mueller RJ; Stussi G; Odermatt B; Halter J; Schanz U; Seebach JD
    Xenotransplantation; 2006 Mar; 13(2):126-32. PubMed ID: 16623806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic red blood cell exchange for prevention of severe immune hemolysis in minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation after reduced-intensity conditioning.
    Worel N; Greinix HT; Supper V; Leitner G; Mitterbauer M; Rabitsch W; Fischer G; Rosenmayr A; Höcker P; Kalhs P
    Transfusion; 2007 Aug; 47(8):1494-502. PubMed ID: 17655594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of ABO incompatibility on allogeneic peripheral blood progenitor cell transplantation after reduced intensity conditioning.
    Canals C; Muñiz-Díaz E; Martínez C; Martino R; Moreno I; Ramos A; Arilla M; Boto N; Pastoret C; Remacha A; Sierra J; Madoz P
    Transfusion; 2004 Nov; 44(11):1603-11. PubMed ID: 15504166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence that donor intrinsic response to G-CSF is the best predictor of acute graft-vs-host disease following allogeneic peripheral blood stem cell transplantation.
    Dhédin N; Chamakhi I; Perreault C; Roy DC; Sauvageau G; Ducruet T; Busque L; Fish D; Bélanger R; Roy J
    Exp Hematol; 2006 Jan; 34(1):107-14. PubMed ID: 16413397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transient anti rhesus alloantibody produced by graft after non-myeloablative allogeneic stem cell transplant.
    Contentin N; Lenain P; Chamouni P; Hau F; Bastit D; Buchonnet G; Tilly H
    Transfus Apher Sci; 2004 Dec; 31(3):191-7. PubMed ID: 15556466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Granulocyte-colony-stimulating factor-mobilized prophylactic granulocyte transfusions given after allogeneic peripheral blood progenitor cell transplantation result in a modest reduction of febrile days and intravenous antibiotic usage.
    Oza A; Hallemeier C; Goodnough L; Khoury H; Shenoy S; Devine S; Augustin K; Vij R; Trinkaus K; Dipersio JF; Adkins D
    Transfusion; 2006 Jan; 46(1):14-23. PubMed ID: 16398726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of pure red cell aplasia after major ABO-incompatible peripheral blood stem cell transplantation by induction of chronic graft-versus-host disease.
    Yamaguchi M; Sakai K; Murata R; Ueda M
    Bone Marrow Transplant; 2002 Oct; 30(8):539-41. PubMed ID: 12379896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinically significant anti-A(1) in a presumed ABO-identical hematopoietic stem cell transplant recipient: a case report.
    Jaben EA; Jacob EK; Tauscher C; D'Souza A; Hogan WJ; Stubbs JR
    Transfusion; 2013 Jan; 53(1):202-5. PubMed ID: 22574682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe hemolytic anemia due to multiple red cell alloantibodies after an ABO-incompatible allogeneic bone marrow transplant.
    López A; de la Rubia J; Arriaga F; Jiménez C; Sanz GF; Carpio N; Marty ML
    Transfusion; 1998 Mar; 38(3):247-51. PubMed ID: 9563404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies.
    Helbig G; Stella-Holowiecka B; Wojnar J; Krawczyk M; Krzemien S; Wojciechowska-Sadus M; Markiewicz M; Wylezol I; Kopera M; Holowiecki J
    Ann Hematol; 2007 Sep; 86(9):677-83. PubMed ID: 17486341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transfusion policy: when to stop the use of extremely rare blood for an allogeneic hematopoietic progenitor cell transplant recipient with a history of red cell alloimmunization.
    Senzel L; Boulad F; Wuest D; Reid ME
    Transfusion; 2007 May; 47(5):781-7. PubMed ID: 17465941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of blood group differences in allogeneic hematopoietic peripheral blood progenitor cell transplantation.
    Erker CG; Steins MB; Fischer RJ; Kienast J; Berdel WE; Sibrowski W; Cassens U
    Transfusion; 2005 Aug; 45(8):1382-90. PubMed ID: 16078929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A delayed hemolytic transfusion reaction (DHTR) with multiple alloantibodies (Anti-E, Jka, Dia, Fyb, and S) induced by E-antigen-negative, crossmatch-compatible blood.
    Yamane K; Yagihashi A; Sasaki M; Kuwashima K; Morio A; Watanabe N
    Immunopharmacol Immunotoxicol; 1998 Nov; 20(4):531-9. PubMed ID: 9805232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
    Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of reemergent anti-B red blood cell antibodies in a patient with recurrent acute myeloid leukemia with ABO-incompatible allogeneic peripheral blood stem cell transplantation.
    Tajima K; Takizawa K; Yasuda T; Tsumanuma R; Okuyama S; Kumagai H; Omoto E; Okumura W
    Transfusion; 2019 Nov; 59(11):3319-3323. PubMed ID: 31503348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.